4572 — Carna Biosciences Balance Sheet
0.000.00%
- ¥5bn
- ¥3bn
- ¥636m
Annual balance sheet for Carna Biosciences, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 4,299 | 3,818 | 3,379 | 2,889 | 2,108 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 129 | 1,244 | 182 | 788 | 87.1 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 4,708 | 5,318 | 4,104 | 4,191 | 2,738 |
Net Property, Plant And Equipment | 53.3 | 51.6 | 100 | 105 | 0 |
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 4,835 | 5,433 | 4,266 | 4,350 | 2,772 |
Accounts Payable | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 727 | 775 | 436 | 376 | 223 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 1,011 | 1,117 | 625 | 472 | 297 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 3,824 | 4,316 | 3,642 | 3,878 | 2,475 |
Total Liabilities & Shareholders' Equity | 4,835 | 5,433 | 4,266 | 4,350 | 2,772 |
Total Common Shares Outstanding |